BridgeBio Pharma Inc. (BBIO), a biopharmaceutical company focused on genetic diseases, will be presenting additional data on clinical outcomes from ATTRibute-CM at the European Society of Cardiology (ESC) Congress tomorrow.
ATTRibute-CM is a phase III study of the company's investigational drug Acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis demonstrated a significant impact on mortality, hospitalizations, and quality of life in in ATTR-CM participants in the trial.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com